Neuroscience Innovation Forum, March 2022

A FreeMind Group Supported Event

Sachs Associates Neuroscience Innovation Forum March 2022

When: March 22-23, 2022

FreeMind proudly supports the 5th annual Neuroscience Innovation Forum.


The 5th Annual Neuroscience Innovation Forum (NIF) will take place on the 22nd – 23rd of March 2022, with 1:1 meetings 21st – 25th of March during which the online meeting system open for 12 hours a day.

The main programme for the 5th Annual NIF will be spread throughout 2 days. Featuring more than 12 hours of high-level keynotes, panel discussions, and spotlight showcases. The target audience for this event are buy and sell-side analysts from investment banks and funds, as well as partnering executives from pharma, biotech, digital therapeutics and neurotech companies. We anticipate 300+ delegates and 35+ company presentations by established listed, private and growth companies.

The conference will be held in the Eastern Daylight Time (EDT) zone.


Tuesday, 22nd of March:

  • Industry Roundtable: Latest Trends in Partnering and M&A Panel
  • Latest Developments in AD & Dementia Panel
  • Progress with PD & Movement Disorders Panel
  • Rare & Orphan & New Modalities Panel
  • Investor Roundtable

Wednesday, 23rd of March:

  • Advances in Neuropsychiatry Panel
  • Pain, Migraine & Addiction Panel
  • Ophthalmology: Business Development, Licensing & Investment Panel
  • Partnering with Pharma on Digital Biomarkers, Diagnostics & Therapeutics Panel
  • Investing in Advances in Neurotech: Devices, Implants & Neurostimulation Panel

Preliminary Keynote Speakers Include:

  • Keynote: “Life in The Post-Aduhelm CNS World” by Harry Tracy, President, NI Research Inc.

Confirmed Chairs & Speakers Include:

  • Amit Etkin, Founder & CEO, Alto Neuroscience
  • Anna Lisa Picciolo-Lehrke, Head Business Development Neurology, UCB Pharma
  • Aswin Gunasekar, CEO, Zeto, Inc.
  • Audrey Dufour, Director, Corporate Business Development & Strategy, H. Lundbeck A/S
  • Begoña Carreño, Global Head BD&L Ophthalmology, Novartis International AG
  • Beth Shafer, Head of Neuroscience, Drug Discovery Sciences & Externalization BD, Takeda Pharmaceuticals Co., Ltd.
  • Beyhan Zaim, VP of Business Development, Sunovion Pharmaceuticals, Inc.
  • Bibhash Mukhopadhyay, Founder & Managing Partner, Sound Bioventures Management AB
  • Brandon Bentzley, Co-Founder & Chief Science O­fficer, Magnus Medical
  • Brent Vaughan, CEO, Cognito Therapeutics, Inc.
  • Bruce Leuchter, President & CEO, Neurvati Neurosciences, Inc.
  • Bruce Meadows, Managing Partner, Takeda Digital Ventures LP
  • Catherine Abbadie, Global Head S&E, Simcere Pharmaceutical Group
  • Charles Fisher, Founder & CEO, Unlearn.AI, Inc.
  • Charles Stacey, President & CEO, Cerecin Pte. Ltd.
  • Christian Jung, Partner, Dementia Discovery Fund – SV Health Investors LLP
  • Cuong Do, President & CEO, BioVie Inc.
  • Daniel Lee, Managing Director, PJT Partners
  • David Baker, President & CEO, Vallon Pharmaceuticals Inc.
  • David Samler, Chief Executive Officer, Alterity Therapeutics
  • Deborah Rathjen, Executive Chair & CEO, Bioasis Technologies, Inc.
  • Diana Saraceni, Co-Founder & General Partner, Panakès Partners SGR SpA
  • Dmitrij Hristodorov, Partner, Forbion
  • Garth Smith, VP, Business Development & Partnerships, Ontario Brain Institute
  • Gene Kinney, President and Chief Executive Officer, Director, Prothena Corporation
  • Geoffrey Klass, CEO, Sense Neuro Diagnostics
  • Guy Seabrook, Vice President & Global Lead, Neuroscience External Innovation, Johnson & Johnson Innovation LLC
  • Howard Fillit, Founding Executive Director & Chief Science Officer, Alzheimer’s Drug Discovery Foundation
  • Jamil Beg, Partner, 5AM Venture Management LLC
  • Jay Olson, Managing Director & Senior Analyst, Oppenheimer & Co. Inc.
  • Jeffrey Cohen, Managing Director, Equity Research, Healthcare & Medical Technologies, Ladenburg Thalmann & Co. Inc.
  • Ji Li, President & Chief Strategy Officer, AffaMed Therapeutics
  • Kasper Roet, Co-Founder & CEO, QurAlis LLC
  • Kees Been, CEO, BIAL Biotech
  • Keld Flintholm Jørgensen, Executive VP & CBO, H. Lundbeck A/S
  • Laxminarayan Bhat, Founder, President and CEO, Reviva Pharmaceuticals, Inc.
  • Lisa Ricciardi, President & CEO, Cognition Therapeutics, Inc.
  • Lloyd Diamond, President & CEO, PIXIUM VISION SA
  • Lori Badura, VP, Head of Global Neuroscience & Rare Disease Partnering, Ipsen
  • Lynn Durham, Founder & CEO, STALICLA SA
  • Marc Goodman, Managing Director, Senior Research Analyst, SVB Leerink
  • Marc Martinell, Co-Founder & CEO, Minoryx Therapeutics
  • Marco Baptista, VP, Research Programs, The Michael J. Fox Foundation for Parkinson’s Research
  • Matthias Steger, Co-Founder & CEO, Rejuveron Life Sciences AG
  • Nader Yaghoubi, Co-Founder, President & CEO, PathMaker Neurosystems Inc.
  • Manuel López-Figueroa, Scientific Liaison, Pritzker Neuropsychiatric Disorders Research Consortium
  • Murali Gopalakrishnan, Global Head, Neuroscience Search & Evaluation, AbbVie, Inc.
  • Peter Ginsberg, EVP, Corp. Development & CBO, Foundation Fighting Blindness
  • Peter Louwagie, Global Head Business Development & Licensing Neuroscience, Novartis International AG
  • Pradeep Banerjee, Executive Director, AbbVie, Inc.
  • Ralph Kern, President & Chief Medical Officer, BrainStorm Cell Therapeutics, Inc.
  • Randall Stevens, Chief Medical Officer, Centrexion Therapeutics Corp.
  • Reenie McCarthy, CEO, Stealth BioTherapeutics Inc.
  • Sahil Kirpekar, Head of Business Development, Otsuka Pharmaceutical Co., Ltd.
  • Stéphane Thiroloix, Founder, President & CEO, AlgoTherapeutix SAS
  • Steve Tregay, Managing General Partner, Mission BioCapital
  • Sumant Kulkarni, Managing Director, Biotechnology Equity Research, Canaccord Genuity LLC
  • Thomas Cavanagh, Co-Founder & CEO, Oxular Limited
  • Thomas Holm Pedersen, CEO, NMD Pharma
  • Thomas Kim, President & CEO, EpiVario, Inc.
  • Tim Luker, VP Venture Science, Corp BD, Eli Lilly and Company
  • Todd Haim, Director, Office of Strategic Extramural Programs, National Institute on Aging
  • Travis Bond, CEO, Altoida, Inc.
  • Yochi Slonim, Co-Founder & CEO, Anima Biotech, Inc.